Alvogen Voluntary Recalls Nationwide Two Lots of Fentanyl Transdermal System Due to Product Mislabeling

 Alvogen Voluntary Recalls Nationwide Two Lots of Fentanyl Transdermal System Due to Product Mislabeling

Alvogen Voluntary Recalls Nationwide Two Lots of Fentanyl Transdermal System Due to Product Mislabeling

Shots:

  • Alvogen voluntarily nationwide recalled two lots of fentanyl transdermal system 12 mcg/h transdermal patches to the consumer level due to mislabeling on cartons labeled with 12 mcg/h containing 50 mcg/h patches that may results in life threatening or fatal respiratory depression 
  • The mislabeled products are manufactured by 3M Drug Delivery Systems. The mislabeled fentanyl transdermal patches lots include: Lot 180060, 12 mcg/h, expiry date May’20; Lot 180073, 12 mcg/h, expiry date Jun’20. The recall is being conducted under the knowledge of the US FDA
  • The fentanyl transdermal patches are indicated for the management of pain in opioid tolerant patients. Fentanyl is also used as a recreational drug, often mixed with heroin or cocaine and has rapid effect which last< 2hrs.

Click here to read full press release/ article | Ref: Alvogen | Image: Alvogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post